Paraoxonase 1 activity, concentration and genotype in cardiovascular disease
Authors:
- Mike MacknessMMMike Mackness
- Paul DurringtonPDPaul Durrington
- Bharti MacknessBMBharti Mackness
- 1 August 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 15 (4) , 399-404
Abstract
To provide up-to-date information on the most recent advances in the epidemiology, biochemistry and molecular biology of the antiatherosclerotic enzyme paraoxonase 1. Case-control and prospective studies published during the period covered by this review have indicated that paraoxonase 1 ‘status’ (i.e. activity and/or concentration) was a more important coronary heart disease risk factor than the paraoxonase 1 genetic polymorphisms. New findings on the role of paraoxonase 1 in homocysteine metabolism are reviewed, as are advances in the nutritional and pharmacological regulation of paraoxonase 1. The recent controversy over whether paraoxonase 1 or platelet-activating factor acetylhydrolase is responsible for the antioxidant activity of high-density lipoprotein is also addressed. In the light of recent findings, we believe that genetic epidemiological studies of the paraoxonase 1 polymorphisms in relation to coronary heart disease should no longer be undertaken unless they are very large and prospective in nature. More research should be undertaken to discover the biochemical mechanisms underlying the mode of action of paraoxonase 1 and the factors which modulate its activity and/or concentration. Bharti Mackness is funded by the International HDL Research Awards Programme. All authors receive research funding from the British Heart Foundation and Diabetes UK.Keywords
This publication has 47 references indexed in Scilit:
- The paraoxonase gene family and coronary heart diseaseCurrent Opinion in Lipidology, 2002
- Paraoxonase and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Apolipoprotein A-I Promotes the Formation of Phosphatidylcholine Core Aldehydes That Are Hydrolyzed by Paraoxonase (PON-1) during High Density Lipoprotein Oxidation with a Peroxynitrite DonorJournal of Biological Chemistry, 2001
- How high-density lipoprotein protects against the effects of lipid peroxidationCurrent Opinion in Lipidology, 2000
- Human Serum Paraoxonases (PON1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic LesionsCirculation, 2000
- Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase ActivitiesArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.Journal of Clinical Investigation, 1998
- Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.Journal of Clinical Investigation, 1995
- Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonaseAtherosclerosis, 1993
- Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoproteinFEBS Letters, 1991